Brief: Ascletis Announces Completion Of Patient Enrollment In Phase II Clinical Trial Of Asc42
30/03/2022 11:31
March 30 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN
PHASE II
CLINICAL TRIAL OF ASC42, AN IN-HOUSE DEVELOPED, BEST-IN-CLASS
FXR AGONIST FOR CHRONIC HEPATITIS B INDICATION
Source text for Eikon: ID:nPn8nhvcZa
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026